In a Law360 article, life sciences partners Michael Beauvais and Marc Rubenstein discussed the 2024 life sciences dealmaking outlook at the JP Morgan Healthcare Conference in San Francisco.
Michael, who advises life sciences and healthcare companies on M&A and financings, notes a bullish industry outlook and sees it in active deals that are currently not public.
Michael said that companies need to be mindful of antitrust scrutiny earlier in the merger process, as soon as they begin courting targets and drafting documents. "Pre-signing, greater antitrust diligence is absolutely critical,” said Michael.
Marc said the life sciences and healthcare initial public offering (IPO) market feels like it may picking up. "There are IPOs in the pipeline. The mantra now is optionality,” said Marc.
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.